Novo Nordisk presents trial outcomes of Xultophy for kind 2 diabetes


Novo Nordisk said Monday that its type 2 diabetes treatment Xultophy showed superior efficacy in reducing hemoglobin A1c (HbA1c) levels, weight change and lower dose hypoglycemia events in phase 3 clinical trials has shown.

Novo Nordisk CEO Rana Asfar Zafar (left) opens a symposium to celebrate the launch of the company’s new type 2 diabetes drug Xultophy at the Grand InterContinental Seoul Parnas.

Lee Eun-jeong, professor at Kangbuk Samsung Hospital, and Cho Young-min, professor at Seoul National University Hospital, recently presented their study results at a symposium to celebrate the launch of the new drug.

People with type 2 diabetes, whose blood sugar levels are unresponsive to insulin glargine U100 and metformin, were treated with Xultophy from Novo Nordisk and demonstrated a non-inferiority of the glycated hemoglobin reduction effect on HbA1c changes compared to people who received a Combination of insulin glargine U100 and insulin aspart ingested therapy, they said.

People treated with Xultophy also saw a 0.9 kg weight loss compared to people who gained 2.6 kg treated with insulin glargine U100 and insulin aspart, which showed excellent effectiveness in controlling weight gain .

Xultophy also reduced the risk of developing hypoglycemia by 89 percent compared to those treated with insulin glargine U100 and insulin aspart.

The company conducted the study for 26 weeks with 506 type 2 diabetes patients whose blood sugar levels were unresponsive to insulin glargine U100 and metformin.

“We held the workshop to stimulate the interest of medical professionals in Xultophy, which offers improved control of blood sugar levels and weight gain over existing insulin and oral hypoglycemics or insulin glargine,” said Rana Asfar Zafar, CEO of Novo Nordisk .

Zafar added that the company hopes that Korean type 2 diabetics who have difficulty controlling blood sugar levels, weight management and hypoglycemia can enjoy an improved quality of life through various treatment options.

Xultophy is combined with a fixed ratio of Tresiba (ingredient: insulin degludec) and (ingredient: liraglutide) and controls the blood sugar level in adults with type 2 diabetes.

Patients can inject Xultophy, which contains a glucagon-like peptide-1 (GLP-1) receptor agonist and basal insulin, once at any time in the day, regardless of a meal.